Institutional shares held 115 Million
127K calls
38.3K puts
Total value of holdings $3.19B
$3.53M calls
$1.06M puts
Market Cap $3.69B
134,174,000 Shares Out.
Institutional ownership 85.68%
# of Institutions 216


Latest Institutional Activity in DNLI

Top Purchases

Q3 2024
Creative Planning Shares Held: 60.3K ($1.66M)
Q3 2024
Vela Investment Management, LLC Shares Held: 15.6K ($429K)
Q3 2024
China Universal Asset Management Co., Ltd. Shares Held: 27.5K ($756K)
Q3 2024
N Verses Capital, LLC Shares Held: 9.9K ($272K)
Q3 2024
Integrated Advisors Network LLC Shares Held: 9.71K ($267K)

Top Sells

Q3 2024
Abrdn PLC Shares Held: 364K ($9.99M)
Q3 2024
New York State Common Retirement Fund Shares Held: 150K ($4.12M)
Q3 2024
Sg Americas Securities, LLC Shares Held: 4.81K ($132K)
Q3 2024
Us Bancorp \De\ Shares Held: 1.17K ($32.1K)
Q3 2024
Allspring Global Investments Holdings, LLC Shares Held: 5.68K ($156K)

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.


Insider Transactions at DNLI

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
341K Shares
From 14 Insiders
Grant, award, or other acquisition 251K shares
Exercise of conversion of derivative security 90K shares
Sell / Disposition
385K Shares
From 7 Insiders
Open market or private sale 345K shares
Bona fide gift 40K shares

Track Institutional and Insider Activities on DNLI

Follow Denali Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DNLI shares.

Notify only if

Insider Trading

Get notified when an Denali Therapeutics Inc. insider buys or sells DNLI shares.

Notify only if

News

Receive news related to Denali Therapeutics Inc.

Track Activities on DNLI